Zai Lab Ltd. has announced an update on Amgen's Phase 3 FORTITUDE-101 study evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) for first-line gastric cancer treatment. The final analysis of the trial has been completed, revealing that while the bemarituzumab plus chemotherapy regimen initially demonstrated a clinically and statistically significant improvement in overall survival compared to chemotherapy alone, the magnitude of this survival benefit has lessened in the final analysis. The results from both the interim and final analyses are slated to be presented at an upcoming major medical meeting. Zai Lab plans to await the results of the FORTITUDE-102 study, which is evaluating bemarituzumab in combination with nivolumab and chemotherapy in the same patient population, before proceeding with regulatory filings. The data readout from FORTITUDE-102 is expected by the end of 2025 or the first half of 2026.